Kinetic studies to elucidate impaired metabolism of triglyceride-rich lipoproteins in humans

Frontiers in Physiology

Volumn 6, Issue NOV, 2015, Pages

  Adiels, Martin ^a,b   Mardinoglu, Adil ^c,d   Taskinen, Marja Riitta ^e   Borén, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

ApoB; Kinetics; Multocomnpartmental modeling; Stable isotopes; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRACER; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID METABOLISM; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POPULATION DYNAMICS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT;

EID: 84949673329     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00342     Document Type: Review

References (66)

1. Adiels, M., Larsson, T., Sutton, P., Taskinen, M. R., Boren, J., and Fielding, B. A. (2010). Optimization of N-methyl-N-[tert-butyldimethylsilyl]trifluoroacetamide as a derivatization agent for determining isotopic enrichment of glycerol in very-low density lipoproteins. Rapid Commun. Mass Spectrom. 24, 586-592. doi: 10.1002/rcm.4422.
2. Adiels, M., Matikainen, N., Westerbacka, J., Soderlund, S., Larsson, T., Olofsson, S. O., et al. (2012). Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 222, 222-228. doi: 10.1016/j.atherosclerosis.2012.02.001.
3. Adiels, M., Olofsson, S. O., Taskinen, M. R., and Boren, J. (2006a). Diabetic dyslipidaemia. Curr. Opin. Lipidol. 17, 238-246. doi: 10.1097/01.mol.0000226115.97436.c0.
4. Adiels, M., Olofsson, S. O., Taskinen, M. R., and Boren, J. (2008). Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225-1236. doi: 10.1161/ATVBAHA.107.160192.
5. Adiels, M., Packard, C., Caslake, M. J., Stewart, P., Soro, A., Westerbacka, J., et al. (2005). A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J. Lipid Res. 46, 58-67. doi: 10.1194/jlr. M400108-JLR200.
6. Adiels, M., Taskinen, M. R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., et al. (2006b). Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755-765. doi: 10.1007/s00125-005-0125-z.
7. Adiels, M., Westerbacka, J., Soro-Paavonen, A., Häkkinen, A. M., Vehkavaara, S., Caslake, M. J., et al. (2007). Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50, 2356-2365. doi: 10.1007/s00125-007-0790-1.
8. Barrett, P. H., Bell, B. M., Cobelli, C., Golde, H., Schumitzky, A., Vicini, P., et al. (1998). SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 47, 484-492. doi: 10.1016/S0026-0495(98)90064-6.
9. Barrett, P. H., Chan, D. C., and Watts, G. F. (2006). Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J. Lipid Res. 47, 1607-1619. doi: 10.1194/jlr. R600017-JLR200.
10. Beal, S. L., and Sheiner, L. B. (1982). Estimating population kinetics. Crit. Rev. Biomed. Eng. 8, 195-222.
11. Berglund, M., Adiels, M., Taskinen, M. R., Boren, J., and Wennberg, B. (2015). Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models. PLoS ONE 10:e0138538. doi: 10.1371/journal.pone.0138538.
12. Berglund, M., Sunnåker, M., Adiels, M., Jirstrand, M., and Wennberg, B. (2012). Investigations of a compartmental model for leucine kinetics using non-linear mixed effects models with ordinary and stochastic differential equations. Math. Med. Biol. 29, 361-384. doi: 10.1093/imammb/dqr021.
13. Boren, J., Matikainen, N., Adiels, M., and Taskinen, M. R. (2014). Postprandial hypertriglyceridemia as a coronary risk factor. Clin. Chim. Acta 431, 131-142. doi: 10.1016/j.cca.2014.01.015.
14. Boren, J., Taskinen, M. R., Olofsson, S. O., and Levin, M. (2013). Ectopic lipid storage and insulin resistance: a harmful relationship. J. Intern. Med. 274, 25-40. doi: 10.1111/joim.12071.
15. Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., et al. (2015). Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity. Multicenter tracer kinetic study. Arterioscler. Thromb. Vasc. Biol. 35, 2218-2224. doi: 10.1161/ATVBAHA.115.305614.
16. Brunzell, J. D., Hazzard, W. R., Porte, D. Jr., and Bierman, E. L. (1973). Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 52, 1578-1585. doi: 10.1172/JCI107334.
17. Chan, D. C., Barrett, P. H., Ooi, E. M., Ji, J., Chan, D. T., and Watts, G. F. (2009). Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J. Clin. Endocrinol. Metab. 94, 989-997. doi: 10.1210/jc.2008-1457.
18. Chan, D. C., Barrett, P. H., and Watts, G. F. (2004a). Lipoprotein transport in the metabolic syndrome (Part I): methodological aspects of stable isotope kinetic studies. Clin. Sci. (Lond.) 107, 221-232. doi: 10.1042/CS20040108.
19. Chan, D. C., Barrett, P. H., and Watts, G. F. (2004b). Lipoprotein transport in the metabolic syndrome (Part II): Pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin. Sci. (Lond.) 107, 233-249. doi: 10.1042/CS20040109.
20. Chan, D. C., Watts, G. F., Gan, S., Wong, A. T., Ooi, E. M., and Barrett, P. H. (2010). Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. Arterioscler. Thromb. Vasc. Biol. 30, 1043-1050. doi: 10.1161/ATVBAHA.109.202275.
21. Denti, P., Bertoldo, A., Vicini, P., and Cobelli, C. (2009). Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling. IEEE Trans. Biomed. Eng. 56, 2156-2166. doi: 10.1109/TBME.2009.2020171.
22. Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., et al. (2009). Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. U.S.A. 106, 15430-15435. doi: 10.1073/pnas.0904944106.
23. Grundy, S. M., Mok, H. Y. I., Zech, L., Steinberg, D., and Berman, M. (1979). Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J. Clin. Invest. 63, 1274-1283. doi: 10.1172/JCI109422.
24. Hiukka, A., Fruchart-Najib, J., Leinonen, E., Hilden, H., Fruchart, J. C., and Taskinen, M. R. (2005). Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 48, 1207-1215. doi: 10.1007/s00125-005-1753-z.
25. Huard, K., Bourgeois, P., Rhainds, D., Falstrault, L., Cohn, J. S., and Brissette, L. (2005). Apolipoproteins C-II and C-III inhibit selective uptake of low-and high-density lipoprotein cholesteryl esters in HepG2 cells. Int. J. Biochem. Cell Biol. 37, 1308-1318. doi: 10.1016/j.biocel.2005.01.005.
26. Hussain, M. M. (2014). Intestinal lipid absorption and lipoprotein formation. Curr. Opin. Lipidol. 25, 200-206. doi: 10.1097/MOL.0000000000000084.
27. Lamon-Fava, S., Diffenderfer, M. R., Barrett, P. H., Buchsbaum, A., Matthan, N. R., Lichtenstein, A. H., et al. (2007). Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48, 1746-1753. doi: 10.1194/jlr. M700067-JLR200.
28. Largajolli, A., Bertoldo, A., and Cobelli, C. (2012). Identification of the glucose minimal model by stochastic nonlinear-mixed effects methods. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 5482-5485. doi: 10.1109/embc.2012.6347235.
29. Lewis, G. F., Uffelman, K. D., Szeto, L. W., and Steiner, G. (1993). Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42, 833-842. doi: 10.2337/diab.42.6.833.
30. MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., et al. (2007). Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117, 153-164. doi: 10.1172/JCI29154.
31. Magkos, F., Fabbrini, E., Korenblat, K., Okunade, A. L., Patterson, B. W., and Klein, S. (2011). Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. Int. J. Obes. (Lond). 35, 1233-1240. doi: 10.1038/ijo.2010.265.
32. Magkos, F., Fabbrini, E., Mohammed, B. S., Patterson, B. W., and Klein, S. (2010). Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18, 1510-1515. doi: 10.1038/oby.2010.90.
33. Mahley, R. W., Innerarity, T. L., Rall, S. C. Jr., and Weisgraber, K. H. (1984). Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 25, 1277-1294.
34. Mahley, R. W., and Ji, Z. S. (1999). Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40, 1-16.
35. Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., and Nielsen, J. (2014). Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083. doi: 10.1038/ncomms4083.
36. Mardinoglu, A., and Nielsen, J. (2015). New paradigms for metabolic modeling of human cells. Curr. Opin. Biotechnol. 34, 91-97. doi: 10.1016/j.copbio.2014.12.013.
37. Neuschwander-Tetri, B. A., and Caldwell, S. H. (2003). Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 1202-1219. doi: 10.1053/jhep.2003.50193.
38. Ninomiya, J. K., L'Italien, G., Criqui, M. H., Whyte, J. L., Gamst, A., and Chen, R. S. (2004). Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109, 42-46. doi: 10.1161/01.CIR.0000108926.04022.0C.
39. O'Brien, E. J., Monk, J. M., and Palsson, B. O. (2015). Using genome-scale models to predict biological capabilities. Cell 161, 971-987. doi: 10.1016/j.cell.2015.05.019.
40. Ooi, E. M., Watts, G. F., Farvid, M. S., Chan, D. C., Allen, M. C., Zilko, S. R., et al. (2005). High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes. Res. 13, 1008-1016. doi: 10.1038/oby.2005.118.
41. Packard, C. J., Gaw, A., Demant, T., and Shepherd, J. (1995). Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. J. Lipid Res. 36, 172-187.
42. Padilla, N., Maraninchi, M., Béliard, S., Berthet, B., Nogueira, J. P., Wolff, E., et al. (2014). Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans. Arterioscler. Thromb. Vasc. Biol. 34, 2330-2337. doi: 10.1161/ATVBAHA.114.303849.
43. Patterson, B. W., Mittendorfer, B., Elias, N., Satyanarayana, R., and Klein, S. (2002). Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J. Lipid Res. 43, 223-233.
44. Pont, F., Duvillard, L., Florentin, E., Gambert, P., and Verges, B. (2002). High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int. J. Obes. Relat. Metab. Disord. 26, 1151-1158. doi: 10.1038/sj.ijo.0802070.
45. Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., and Scott, J. (1987). A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 50, 831-840. doi: 10.1016/0092-8674(87)90510-1.
46. Ramakrishnan, S., and Ginsberg, H. (2015). "Modeling the VLDL delipidation cascade: apolipoprotein B and triglyceride pools have identical rate constants despite different fates and mass distributions," in 17th ISA Congress (Amsterdam).
47. Ray, K. (2013). NAFLD-the next global epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 621. doi: 10.1038/nrgastro.2013.197.
48. Sacks, F. M., Zheng, C., and Cohn, J. S. (2011). Complexities of plasma apolipoprotein C-III metabolism. J. Lipid Res. 52, 1067-1070. doi: 10.1194/jlr. E015701.
49. Segrest, J. P., Jones, M. K., De Loof, H., and Dashti, N. (2001). Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346-1367.
50. Sondergaard, E., Sorensen, L. P., Rahbek, I., Gormsen, L. C., Christiansen, J. S., and Nielsen, S. (2012). Postprandial VLDL-triacylglycerol secretion is not suppressed in obese type 2 diabetic men. Diabetologia 55, 2733-2740. doi: 10.1007/s00125-012-2624-z.
51. Sørensen, L. P., Andersen, I. R., Søndergaard, E., Gormsen, L. C., Schmitz, O., Christiansen, J. S., et al. (2011). Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes 60, 88-96. doi: 10.2337/db10-0564.
52. Sun, F., Stolinski, M., Shojaee-Moradie, F., Lou, S., Ma, Y., Hovorka, R., et al. (2013). A novel method for measuring intestinal and hepatic triacylglycerol kinetics. Am. J. Physiol. Endocrinol. Metab. 305, E1041-E1047. doi: 10.1152/ajpendo.00105.2013.
53. Targher, G., Marra, F., and Marchesini, G. (2008). Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51, 1947-1953. doi: 10.1007/s00125-008-1135-4.
54. Taskinen, M. R. (2003). Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46, 733-749. doi: 10.1007/s00125-003-1111-y.
55. Taskinen, M. R. (2005). Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 5, 297-308. doi: 10.2174/1566524053766086.
56. Taskinen, M. R., Adiels, M., Westerbacka, J., Soderlund, S., Kahri, J., Lundbom, N., et al. (2011). Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler. Thromb. Vasc. Biol. 31, 2144-2150. doi: 10.1161/ATVBAHA.111.224808.
57. Taskinen, M. R., and Boren, J. (2015). New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239, 483-495. doi: 10.1016/j.atherosclerosis.2015.01.039.
58. Tremblay, A. J., Lamarche, B., Labonte, M. E., Lepine, M. C., Lemelin, V., and Couture, P. (2014). Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Am. J. Clin. Nutr. 99, 54-61. doi: 10.3945/ajcn.113.068767.
59. Verges, B., Adiels, M., Boren, J., Barrett, P. H., Watts, G. F., Chan, D., et al. (2014). Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. J. Clin. Endocrinol. Metab. 99, 4281-4290. doi: 10.1210/jc.2014-2365.
60. Vernon, G., Baranova, A., and Younossi, Z. M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274-285. doi: 10.1111/j.1365-2036.2011.04724.x.
61. Williams, K. J. (2008). Molecular processes that handle-and mishandle-dietary lipids. J. Clin. Invest. 118, 3247-3259. doi: 10.1172/JCI35206.
62. Williams, K. J., and Chen, K. (2010). Recent insights into factors affecting remnant lipoprotein uptake. Curr. Opin. Lipidol. 21, 218-228. doi: 10.1097/MOL.0b013e328338cabc.
63. Wong, A. T., Chan, D. C., Barrett, P. H., Adams, L. A., and Watts, G. F. (2014a). Effect of omega-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J. Clin. Endocrinol. Metab. 99, E1427-E1435. doi: 10.1210/jc.2013-4037.
64. Wong, A. T., Chan, D. C., Pang, J., Watts, G. F., and Barrett, P. H. (2014b). Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state. J. Clin. Endocrinol. Metab. 99, E122-E126. doi: 10.1210/jc.2013-2477.
65. Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., and Lewis, G. F. (2014). Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 63, 2394-2401. doi: 10.2337/db13-1654.
66. Zech, L. A., Grundy, S. M., Steinberg, D., and Berman, M. (1979). Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects. J. Clin. Invest. 63, 1262-1273. doi: 10.1172/JCI109421.